{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/tamoxifen-managing-adverse-effects/how-up-to-date-is-this-topic/changes/","result":{"pageContext":{"chapter":{"id":"822375d2-f573-54dc-9af4-4cafe8094b70","slug":"changes","fullItemName":"Changes","depth":2,"htmlHeader":"<!-- begin field 1a1e3786-e4b6-4aaa-ac4b-db913aafa4e7 --><h2>Changes</h2><!-- end field 1a1e3786-e4b6-4aaa-ac4b-db913aafa4e7 -->","summary":null,"htmlStringContent":"<!-- begin item 542406c2-8a5a-4192-9d4c-bddc4da45cbb --><!-- begin field a7a6d345-aa73-4d78-b595-b694501bdb82 --><p><strong>November 2019</strong> — reviewed. A literature search was conducted in November 2019 to identify evidence-based guidelines, UK policy, systematic reviews, and key randomized controlled trials published since the last revision of this topic. Primary prevention of breast cancer in women at moderate or high risk has been included as a licensed indication for tamoxifen, as per the manufacturer's Summary of Product Characteristics (SPC) and the British National Formulary (BNF). No changes to clinical recommendations have been made. </p><!-- end field a7a6d345-aa73-4d78-b595-b694501bdb82 --><!-- end item 542406c2-8a5a-4192-9d4c-bddc4da45cbb -->","topic":{"id":"843d50d1-29e0-5a25-b29d-4d009d4ca56b","topicId":"3c8ceccf-c939-4885-bf43-dff38de8f940","topicName":"Tamoxifen - managing adverse effects","slug":"tamoxifen-managing-adverse-effects","lastRevised":"Last revised in November 2019","chapters":[{"id":"68b30489-1c21-5691-aa91-d98c85819055","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"3902ae23-4436-5f34-954f-61ee513623ad","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"9c316fc9-3054-50cd-8e92-91608fd623e3","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"822375d2-f573-54dc-9af4-4cafe8094b70","slug":"changes","fullItemName":"Changes"},{"id":"4fc88cec-4de4-5284-976a-8ff9c926937b","slug":"update","fullItemName":"Update"}]},{"id":"3254e7b2-0406-5c0f-bd0a-d382915875ec","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"853ae85c-163b-5ccf-a644-b072b18b9fca","slug":"goals","fullItemName":"Goals"},{"id":"c3b62b71-183a-5bee-bd03-125e3b658e3c","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"4bae49ff-a702-5f72-b2d0-f46009108792","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"dbdc028f-d934-59f6-91ca-bf671c6ed1bd","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"3b6ca9fb-1d57-5cbb-9532-96c1bff9189d","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"8ca455d2-3037-5131-bb24-2196750b0f52","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"204b504a-d22b-5a27-a20f-f08f20c3591b","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"69c80182-34aa-574b-8416-bc35ff6b2570","slug":"definition","fullItemName":"Definition"}]},{"id":"1f50f511-890e-545d-8d87-c607a1a4d1e2","fullItemName":"Management","slug":"management","subChapters":[{"id":"fc761c4a-bd2a-5463-96c8-861d67a66e30","slug":"tamoxifen-prescribing-information","fullItemName":"Scenario: Tamoxifen - prescribing information"}]},{"id":"f7ed77db-551a-5fd6-92d5-f93f53a97371","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"da6173b5-10a1-58a6-9931-e08d1f99d6c0","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"ae24edbd-49ce-530e-9e4b-4367a855974e","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"4fa9ad0b-2994-5c86-99d2-265267b32373","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"bbed3b56-4479-5b7a-a72a-79307a374780","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"ebc820e0-9d21-571c-b402-0ca097dbf174","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"0e2cc02a-ab60-597e-a108-ae6b27aafd5d","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"41fcafe7-39c4-51a2-b67a-c091704fdf89","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"9c316fc9-3054-50cd-8e92-91608fd623e3","slug":"how-up-to-date-is-this-topic","fullItemName":"How up-to-date is this topic?"},"subChapters":[{"id":"5d818c48-47e5-575e-adb7-002f14150477","slug":"previous-changes","fullItemName":"Previous changes","depth":3,"htmlHeader":"<!-- begin field 413893d4-a441-4908-8540-cdaceb0f025b --><h3>Previous changes</h3><!-- end field 413893d4-a441-4908-8540-cdaceb0f025b -->","summary":null,"htmlStringContent":"<!-- begin item 63ff72c7-7814-498d-a3a1-a7c487497c36 --><!-- begin field d97b24ba-b2d8-4ecc-b37b-53ca49a64051 --><p><strong>December 2014 </strong>— reviewed. A literature search was conducted in October 2014 to identify evidence-based guidelines, UK policy, systematic reviews, and key randomized controlled trials published since the last revision of this topic. The scope of the topic has been changed to cover the general prescribing information on tamoxifen, and the topic structure has been changed to reflect this.</p><p><strong>November 2012 </strong>— minor update. The links to the electronic medicines compendium (emc) website (<a data-hyperlink-id=\"4296f66e-8673-42e1-aff7-a98d013328e1\" href=\"http://www.medicines.org.uk/\">www.medicines.org.uk</a>) have been updated.</p><p><strong>January 2012 </strong>— minor update. Added updated information from the manufacturer's Summary of Product Characteristics (SPC) stating that venlafaxine may alter glycaemic control in people with diabetes mellitus. Issued in January 2012.</p><p><strong>October 2008 to February 2009 </strong>— this is a new CKS topic. The evidence base has been reviewed in detail, and recommendations are clearly justified and transparently linked to the supporting evidence.</p><!-- end field d97b24ba-b2d8-4ecc-b37b-53ca49a64051 --><!-- end item 63ff72c7-7814-498d-a3a1-a7c487497c36 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}